<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50729">Mitoxantrone</z:chebi> (Mito) is presently used in an increasing number of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including <z:hpo ids='HP_0001909'>leukemias</z:hpo>, <z:hpo ids='HP_0003002'>breast carcinomas</z:hpo> and <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>With it has come increased incidence of post remission cytopenias and delayed engraftment following autologous bone marrow transplantation (ABMT) </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated engraftment in 18 patients who underwent allogeneic BMT (allo-BMT) following a preparative regimen that included high dose Mito (60 mg m2) </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients with malignant disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> 10, ALL 3, <z:mp ids='MP_0005481'>CML</z:mp> 2, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 1) and two with non-malignant disease (<z:mp ids='MP_0002536'>SCID</z:mp> 1, <z:hpo ids='HP_0011002'>osteopetrosis</z:hpo> 1) underwent non-T cell depleted allo-BMT </plain></SENT>
<SENT sid="4" pm="."><plain>Fourteen patients with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were transplanted at an advanced stage of disease while only two patients were standard risk patients </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 18 patients, 12 were females and six males, with a median age of 30.5 (0.3-48) years </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients, (<z:hpo ids='HP_0003002'>breast cancer</z:hpo> 3, malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 4 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> 2), who underwent ABMT following preparative regimens with comparable doses of Mito, served as controls </plain></SENT>
<SENT sid="7" pm="."><plain>Engraftment following allo-BMT was <z:mpath ids='MPATH_458'>normal</z:mpath> and not statistically different from engraftment following ABMT </plain></SENT>
<SENT sid="8" pm="."><plain>Five patients, who underwent allo-BMT, developed &gt;grade II <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) and two developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="9" pm="."><plain>After a median follow up of 28 (6-42) months, five patients are alive (one with disease) </plain></SENT>
<SENT sid="10" pm="."><plain>In summary, engraftment following high dose Mito and allo-BMT is not statistically different from engraftment following ABMT </plain></SENT>
<SENT sid="11" pm="."><plain>Controlled studies with a larger group of standard risk patients are needed to elucidate the role of Mito in conditioning regimens pre-BMT </plain></SENT>
</text></document>